VeriStrat: a prognostic and/or predictive biomarker for advanced lung cancer patients?

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J. Clin. 63(1), 11–30 (2013).
   PubMed Web of Science ®Google Scholar
• Peters S, Adjei AA, Gridelli C et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23 ( Suppl. 7), vii56–vii64 (2012).
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV et al. Randomizedphase III trial of pemetrexed versus docetaxel in patients with non-small-celllung cancer previously treated with chemotherapy. J. Clin. Oncol. 22(9), 1589–1597 (2004).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372(9652), 1809–1818 (2008).
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Stelmakh L, Cicenas S et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 13(3), 300–308 (2012).
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFRmutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13(3), 239–246 (2012).
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368(25), 2385–2394 (2013).
   PubMed Web of Science ®Google Scholar
• Garassino MC, Martelli O, Broggini M et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 14(10), 981–988 (2013).
   PubMed Web of Science ®Google Scholar
• Okano Y, Ando M, Asami K et al. Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J. Clin. Oncol. 31(Suppl.), Abstract 8006 (2013).
   Google Scholar
• Taguchi F, Solomon B, Gregorc V et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J. Natl Cancer Inst. 99(11), 838–846 (2007).
   PubMedGoogle Scholar
• Roder J, Roder H, Hunsucker S et al. Retrospective Analysis of Study EGF30008 by Mass-Spectrometry Based Serum Assay (VeriStrat®) [Thirty-fourth Annual CTRC-AACR San Antonio Breast Cancer Symposium]. Cancer Research 71, 24( Suppl. 3), S1–S4 (2011).
   Google Scholar
• Milan E, Lazzari C, Anand S et al. SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. J. Proteomics 76, 91–101 (2012).
   Google Scholar
• Hunsucker SH, Grigorieva J, Helfrich BA et al. Pre-treatment sera from NSCLC patients with different outcomes on EGFR-TKI therapy differentially affects sensitivity of lung cancer cell lines to EGFR-TKIs. Cancer Res. 71(8 Suppl.), Abstract LB-306 (2011).
   Google Scholar
• Amann JM, Lee JW, Roder H et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J. Thorac. Oncol. 5(2), 169–178 (2010).
   Google Scholar
• Stinchcombe TE, Roder J, Peterman AH et al. A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer. J. Thorac. Oncol. 8(4), 443–451 (2013).
   PubMed Web of Science ®Google Scholar
• Carbone DP, Ding K, Roder H et al. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR. 21 trial. J. Thorac. Oncol. 7(11), 1653–1660 (2012).
   PubMed Web of Science ®Google Scholar
• Lazzari C, Novello S, Barni S et al. Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE) [2013 ASCO Annual Meeting]. J. Clin. Oncol. 31(Suppl.), Abstract LBA8005 (2013).
   Google Scholar
• S. Novello, S. Barni, F. Grossi et al. Tissue biomarker analysis in PROSE, a randomized proteomic stratified phase III study of second line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (NSCLC). 17th ECCO – 38th ESMO – 32nd ESTRO European Cancer Congress. Amsterdam, Netherlands, 27 September–1 October (2013).
   Google Scholar
• Nelson RE, Stenehjem D, Akerley W. A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis. Lung Cancer doi:10.1016/j.lungcan.2013.08.021 (2013) ( Epub ahead of print).
   Google Scholar